Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 2, 2012, Pages 333-339

  Meng, Li Juan ^a   Wang, Jun ^a   Fan, Wei Fei ^a   Pu, Xiao Lin ^a   Liu, Fu Yin ^a   Yang, Min ^a  

^a Jiangsu Province Geriatric Institute   (China)

Author keywords

Capecitabine; CRPC; CTX; Prednisone; Thalidomide

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER CONTROL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; PREDNISONE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; THALIDOMIDE;

EID: 84857058083     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1101-2     Document Type: Article

References (33)

1. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators (2007) Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgenindependent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 5(6): 669-674 (Pubitemid 350002922)
2. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite eVects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63(15): 4342-4346 (Pubitemid 36951001)
3. Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose eVects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62(23): 6938-6943 (Pubitemid 35424084)
4. Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic eVects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100(22): 12917-12922 (Pubitemid 37340000)
5. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M (2005) Cyclophosphamide- methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer.A comparative pharmacoeconomic evaluation. Ann Oncol 16(8): 1243-1252 (Pubitemid 41166506)
6. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, GriYn T (1998) Preliminary studies of a novel oral Xuoropyrimidine carbamate: capecitabine. J Clin Oncol 16(5): 1795-1802
7. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, StaVurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, ChieVo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators (2010) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 26(21): 1995-2005
8. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26(30): 4899-4905
9. Di LG, Autorino R, De Laurentiis M, Forestieri V, Romano C, Prudente A, Giugliano F, Imbimbo C, Mirone V, De Placido S (2007) Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther 6(3): 313-317 (Pubitemid 47328294)
10. El-Rayes BF, Black CA, Ensley JF (2003) Hormone-refractory prostate cancer responding to capecitabine. Urology 61(2): 462
11. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y (1999) Induction of thymidine phosphorylase expression and enhancement of eYcacy of capecitabine or 5′-deoxy-5- Xuorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83(1): 127-134 (Pubitemid 29409488)
12. Ferrero JM, Chamorey E, Oudard S, Dides S, Lesbats G, Cavaglione G, Nouyrigat P, Foa C, Kaphan R (2006) Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormonerefractory prostate cancer. Cancer 107(4): 738-745 (Pubitemid 44232666)
13. Gasent BJM, Giner MV, Giner-Bosch V, Cerezuela FP, Alberola CV (2011) Phase II trial of oxaliplatin and capecitabine after progression to Wrst-line chemotherapy in androgen-independent prostate cancer patients. Am J Clin Oncol 34(2): 155-159
14. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, ChauVert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK eVector functions in end stage cancer patients. Cancer Immunol Immunother 56(5): 641-648 (Pubitemid 46348738)
15. Gittes RF (1991) Carcinoma of the prostate. N Engl J Med 324(4): 236-245
16. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300
17. Kolodziej M, Neubauer MA, Rousey SR, Pluenneke RE, Perrine G, Mull S, Boehm KA, Ilegbodu D, Asmar L (2006) Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer. Clin Genitourin Cancer 5(2): 155-161
18. Ma CG, Ye DW, Li CL, Zhou FJ, Yao XD, Zhang SL, Dai B, Zhang HL, Zhu Y, Shen YJ (2008) Epidemiology of prostate cancer from three centers and analysis of the Wrst-line hormonal therapy for the advanced disease. Zhonghua Wai Ke Za Zhi 46(12): 921-925
19. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral Xuoropyrimidine carbamate, capecitabine, which generates 5-Xuorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8): 1274-1281 (Pubitemid 28342121)
20. Morant R, Bernhard J, Dietrich D, Gillessen S, Bonomo M, Borner M, Bauer J, Cerny T, Rochlitz C, Wernli M, Gschwend A, Hanselmann S, Hering F, Schmid HP (2004) Capecitabine in hormone- resistant metastatic prostatic carcinoma. Br J Cancer 90(7): 1312-1317 (Pubitemid 38586253)
21. Payne SA (1992) A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35(12): 1505-1509
22. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520 (Pubitemid 39315318)
23. Pu YS (2000) Prostate cancer in Taiwan: epidemiology and risk factors. Int J Androl 23(Suppl 2): 34-36
24. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC (2006) Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer 106(10): 2143-2147 (Pubitemid 43673235)
25. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375(9724): 1437-1446
26. Small EJ, Vogelzang NJ (1997) Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 15(1): 382-388 (Pubitemid 27021526)
27. Spicer J, Plunkett T, Somaiah N, Chan S, Kendall A, Bolunwu N, Pandha H (2005) Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. Prostate Cancer Prostatic Dis 8(4): 364-368 (Pubitemid 43078173)
28. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabrò F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M (2009) Multinational, doubleblind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27(32): 5431-5438
29. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6): 1756-1764 (Pubitemid 26185452)
30. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (15): 1502-1512 (Pubitemid 39315317)
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate theresponse to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216 (Pubitemid 30099779)
32. Vaishampayan UN, Marur S, Heilbrun LK, Cher ML, Dickow B, Smith DW, Al Hasan SA, Eliason J (2009) Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol 182(1): 317-323
33. Yang PQ (2010) Overview of prostate cancer epidemiology. Chin J Med 45(10): 875-877